RESUMEN
Objective: The survival rates of children with acute lymphoblastic leukemia (ALL) have improved over the years, but infections remain a significant cause of morbidity and mortality. Chemotherapy has a range of harmful side effects including the loss of protective antibodies against vaccine-preventable diseases. The objective of this study was to evaluate the serological status of pediatric ALL cases before and after the intensive chemotherapy. Materials and Methods: Children treated and followed up for ALL at Dokuz Eylül University were included in this retrospective cross-sectional study. Antibody levels against hepatitis A, hepatitis B, and rubella were routinely assessed both at the time of diagnosis and six months after completion of chemotherapy. However, measles, mumps, and varicella antibody levels were evaluated just six months after the treatment. Results: Seventy-eight children who completed chemotherapy for ALL were recruited. All participants had nonprotective antibody levels for at least one of the diseases. The highest seropositivity rate was found for hepatitis A (55.1%) and the lowest for measles (17.9%) after chemotherapy. Overall, 50.7%, 30.6%, and 45.7% of the patients significantly lost their humoral immunity against hepatitis B, hepatitis A, and rubella, respectively. Patients in the higher-risk group for ALL had a lower seropositivity rate than the other risk group patients. There were statistically significant relations between the protective antibody rates of hepatitis A and varicella and the age of the patients. Except for the hepatitis A vaccination, pre-chemotherapy vaccination did not affect post-chemotherapy serology. On the other hand, all children with a history of varicella before the diagnosis showed immunity after chemotherapy. Conclusion: All patients, including those previously fully vaccinated, are at great risk of infection due to the decrease in protective antibody levels after chemotherapy. There is a need for routine post-chemotherapy serologic testing and re-vaccination based on the results obtained.
RESUMEN
Introduction: The COVID-19 pandemic significantly impacted the mental health of individuals with chronic conditions such as Wilson's Disease (WD). This study investigates stress, anxiety, depression, quality of life, cognitive function, vaccination rates, infection rates, and perceptions related to the pandemic and vaccines among WD patients. Methods: The study analyzed COVID-19 perceptions and vaccine attitudes of 62 adult WD patients enrolled in the international multisite WD Registry. A subgroup of 33 participants completed a series of mental health scales. The effect of working essentially, income loss, wellness activity initiation, and infection of COVID-19 during the pandemic was observed. Results: Results indicate that, overall, the pandemic did not exacerbate anxiety or cognitive function in WD patients but did lead to increased depression among essential workers. Patients experiencing income loss exhibited higher levels of stress and anxiety. Despite these challenges, WD patients showed high vaccination rates and positive attitudes towards vaccines. Discussion: The findings underscore the significant impact of the pandemic on the mental health of WD patients.
RESUMEN
OBJECTIVE: Wilson's disease (WD) is a metabolic disorder associated with abnormal copper metabolism that results in hepatic, psychiatric, and neurologic symptoms. No investigation of taste function has been made in patients with WD, although olfactory dysfunction has been evaluated. METHODS: Quantitative taste and smell test scores of 29 WD patients were compared to those of 790 healthy controls. Taste was measured using the 53-item Waterless Empirical Taste Test (WETT®) and smell using the 40-item revised University of Pennsylvania Smell Identification Test (R-UPSIT®). Multiple linear regression analysis controlled for age and sex. RESULTS: Average WETT® scores did not differ meaningfully between WD and control subjects (respective medians & IQRs = 32 [28-42] & 34 [27-41]); linear regression coefficient = 1.19, 95% CI [-0.81, 3.19], p = 0.242). In contrast, WD was associated with significantly reduced olfactory function [respective median (IQR) R-UPSIT® scores = 35 (33-37) vs. 37 (35-38); adjusted linear regression coefficient = -1.59, 95% CI [-2.34, -0.833]; p < 0.001)]. Neither olfaction nor taste were influenced by WD symptom subtype [23 (79.3%) were hepatic-predominant; 6 (20.7%) neurologic predominant]; R-UPSIT®, p = 0.774; WETT®, p = 0.912). No effects of primary medication or years since diagnosis (R-UPSIT®, p = 0.147; WETT®, p = 0.935) were found. Weak correlations were present between R-UPSIT® and WETT® scores for both control (r=0.187, p < 0.0001) and WD (r=0.237) subjects, although the latter correlation did not reach the 0.05 α level (p = 0.084). CONCLUSION: Although WD negatively impacts smell function, taste is spared. Research is needed to understand the pathophysiologic mechanisms responsible for this divergence.
Asunto(s)
Degeneración Hepatolenticular , Trastornos del Olfato , Humanos , Olfato/fisiología , Degeneración Hepatolenticular/complicaciones , Degeneración Hepatolenticular/diagnóstico , Gusto , Cobre , Trastornos del Olfato/diagnóstico , Trastornos del Olfato/etiologíaRESUMEN
Objective: The hypothalamic-pituitary-gonadal axis is active during minipuberty, the timing of which coincides with infantile colic. To the best of our knowledge, the relationship between these entities has not been previously investigated. Methods: Saliva samples were collected from 15- to 60-day-old term infants (n=139) between 9 am and 5 pm. Group 1 included infants with infantile colic (n=68, 54.4% female) while the remaining healthy infants constituted Group 2 (n=71, 47.9% female). Salivary levels of estradiol (Esal) in females and testosterone (Tsal) in males were measured by ELISA in duplicate. Results: The median (25th-75th centile) age and birth week for all infants were 33 (29-43) days and 39 (38.1-40) weeks, respectively. Levels of Tsal in males [Group 1, 73.35 (59.94-117.82) pg/mL vs Group 2, 77.66 (56.49-110.08) pg/mL, p=0.956] and Esal in females [Group 1, 3.91 (2.76-5.31) pg/mL vs Group 2, 4.03 (1.63-12.1) pg/mL, p=0.683] were similar. However, in subjects with infantile colic (Group 1), Esal and body mass index (BMI) standard deviation scores of females were slightly correlated (Group 1, rs= 0.393, p=0.016 vs. Group 2, rs= 0.308, p=0.076) and there was a significant correlation between the sampling time and Tsal in males (Group 1, rs= 0.469, p=0.009 vs. Group 2, rs= -0.005, p=0.976). Conclusion: Random salivary sex steroid levels were similar in infants with and without infantile colic. However, in subjects with infantile colic, Esal levels in females were positively correlated with BMI and Tsal levels were higher later in the day among males. Thus, sex steroid production may be altered during minipuberty in subjects with infantile colic.
Asunto(s)
Cólico , Estradiol , Saliva , Testosterona , Humanos , Masculino , Femenino , Cólico/metabolismo , Lactante , Saliva/química , Saliva/metabolismo , Testosterona/análisis , Testosterona/metabolismo , Recién Nacido , Estradiol/análisis , Estradiol/sangre , Estradiol/metabolismo , Estudios de Casos y Controles , Hormonas Esteroides Gonadales/análisis , Hormonas Esteroides Gonadales/metabolismoRESUMEN
This study investigates day-to-day variations in urinary luteinizing hormone (U-LH) concentrations in children, focusing on potential minimization or correction methods. 95 children and adolescents (51 boys, 44 girls, ages 5-17) provided daytime and evening urine samples for U-LH determinations over three consecutive days. No consistent day-to-day differences in U-LH levels were observed, although random variations, particularly in adolescents aged 13 or older, were noted. The net inter-assay CV% for U-LH changes over three days showed high variability, averaging 24.6% to 28.0% for boys and 21.6% to 27.3% for girls, independent of sex, collection time, or U-LH level. To reliably determine total urinary luteinizing hormone immunoreactivity in the pediatric population, it is advisable to collect multiple first-morning voided samples for at least three consecutive days as an interim solution, pending the development of a standardized protocol or correction method for varying urine composition. Strict adherence, especially for adolescents aged 13 or older, is vital.
RESUMEN
Objectives: Previous studies suggest urinary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) measurements by immunofluorometric assays (IFMA) as noninvasive alternatives to serum assays for puberty assessment. However, these studies excluded patients with other endocrine disorders and those taking medications. Besides, the recent discontinuation of IFMA manufacturing is a concern. We explored the utility of luminometric assays (LIA) for urinary gonadotropins and thyroid-stimulating hormone (TSH) determinations in euthyroid patients with thyroid pathologies. Methods: We used LIA and IFMA assays to measure serum and first-morning-voided (FMV) urine LH, FSH, and TSH concentrations in euthyroid patients with various thyroid disorders. Of the 47 euthyroid patients with normal serum TSH (S-TSH) levels, 14 were receiving levothyroxine therapy. Results: FMV total urinary LH (U-LH) concentrations correlated significantly with those measured in serum using either LIA (r=0.67, P<.001) or IFMA (r=0.83, P=.003) in patients not receiving levothyroxine treatment; however, no significant correlation could be detected in patients receiving levothyroxine regardless of the assay method (for LIA: r=0.50, P=.08 and IFMA r=0.44, P=.15). Urinary TSH (U-TSH) concentrations correlated poorly with those in serum in both the untreated and the treated groups (r=-0.13, P=.49, and r=-0.45, P=.11, respectively). Conclusion: FMV total U-LH determinations by LIA can be used to assess pubertal development in patients with thyroid pathology, provided the euthyroid patient is not on levothyroxine treatment. U-TSH measurements by LIA cannot replace invasive S-TSH measurements at least in patients with normal S-TSH levels. Further research may reveal the utility of U-TSH determinations in patients with elevated S-TSH levels.
Asunto(s)
Enfermedades de la Tiroides , Tiroxina , Humanos , Niño , Hormona Luteinizante , Enfermedades de la Tiroides/tratamiento farmacológico , Tirotropina , Hormona Folículo EstimulanteRESUMEN
OBJETIVO: Avaliar se a toxina botulínica tipo A (TB-A) tem efeito similar ao da ovariectomia (OVX) sobre os ossos com relação à densitometria mineral óssea.MÉTODOS: Um total de 51 ratas foi dividido randomicamente em três grupos de 17 animais cada. As ratas no primeiro grupo foram o controle, sem qualquer procedimento cirúrgico (Grupo 1). O Grupo 2 recebeu TB-A, enquanto o Grupo 3 foi submetido a OVX. Um total de 8 UI de TB-A foi injetado na região femoral direita de todas as ratas do Grupo 2. No início do estudo e 14 semanas depois, mediu-se a densidade mineral óssea (DMO) dos fêmures esquerdo e direito de todas as ratas em ambos os grupos.RESULTADOS: Não houve diferença estatisticamente significante entre os grupos com relação à DMO do início do estudo. Na 14ªsemana, a DMO dos fêmures direitos foi estatisticamente superior no Grupo 1 do que nos outros grupos, embora não houvesse diferença com significância estatística entre os Grupos 2 e 3. Os resultados médios da DMO dos fêmures esquerdos no Grupo 3 foram inferiores, com significância estatística, do que os resultados dos Grupos 1 e 2 na 14ª semana.CONCLUSÃO: Os resultados do presente estudo mostraram que a TB-A teve efeito similar ao da OVX sobre a osteoporose, no que diz respeito à DMO. Nível de Evidência I, Estudo Experimental, Controlado em Animais.
OBJECTIVE: To evaluate whether Botulinum toxin-A (BTX-A) has a similar effect to that of ovariectomy (OVX) on bone regarding bone mineral densitometry.METHODS: A total of 51 female rats were randomly divided into three groups of 17 animals each. The rats in the first group formed the control group, without any surgical procedure (Group 1). Group 2 received BTX-A while Group 3 was subjected to OVX. A total of 8 IU of BTX-A was injected into the right femoral region of all rats in Group 2. At baseline and 14 weeks later, bone mineral densities (BMD) of the left and right femurs of all rats in both groups were measured.RESULTS: There was no statistically significant difference between the groups with respect to baseline BMD. At the 14th week the BMD of the right femurs were statistically significantly higher in Group 1 than other groups, although there was no statistically significant difference between Groups 2 and 3. The mean BMD results of the left femur in Group 3 were statistically significantly lower than the results in Groups 1 and 2 at the 14th week.CONCLUSION: The results of the current study showed that BTX-A had a similar effect to that of OVX on osteoporosis regarding BMD. Evidence Level I, Experimental, Controlled, Animal Study.